Literature DB >> 26440366

Follicular Thyroid Carcinoma: How Have Histologic Diagnoses Changed in the Last Half-Century and What Are the Prognostic Implications?

Nicole A Cipriani1, Sapna Nagar2, Sharone P Kaplan3, Michael G White3, Tatjana Antic1, Peter M Sadow4, Briseis Aschebrook-Kilfoy5, Peter Angelos3, Edwin L Kaplan3, Raymon H Grogan3.   

Abstract

BACKGROUND: Follicular thyroid carcinoma (FTC) comprises 10% of differentiated thyroid cancers. Diagnostic controversy and interobserver variability render the practical diagnosis of FTC difficult. Overall survival rates vary (46-97%). The aims of this study were to review FTC histologically at the authors' tertiary care institution and to evaluate long-term survival and recurrence.
METHODS: Diagnostic slides from 66 FTC cases (1965-2007) were reviewed by three pathologists from two institutions (blinded to clinical outcomes), and consensus was obtained. Patient demographics, tumor characteristics, and treatment, survival, and recurrence data were collected. Thyroid cancer-specific and recurrence-free survival were calculated by original and reclassified diagnoses.
RESULTS: Forty-seven cases (71%) were reclassified: 24 (36%) to papillary thyroid carcinoma (PTC), 18 (27%) to follicular adenoma (FA), and five (8%) to poorly differentiated carcinoma (PDC). Nineteen (29%) maintained a diagnosis of FTC. The extent of surgical resection and rates of radioiodine treatment did not differ by reclassification diagnosis. Pre-review FTC-specific survival was 83.5% and 75.1% at 10 and 20 years, respectively. Following contemporary reclassification, FTC-specific survival was 77% and 33.7% at 10 and 20 years, respectively. There were no cancer-specific deaths in the FA or PTC groups.
CONCLUSIONS: Over the past 50 years, changes in our understanding of the pathogenesis, histology, and behavior of thyroid carcinoma may partially account for the changes in histologic diagnosis. Elimination of PTC and FA "contaminants" led to decrease in survival following reclassification. Variability in histologic interpretation contributes to diagnostic challenges in follicular lesions. Histologic review of thyroid tumors for research studies is crucial, especially given the ever-changing diagnostic criteria.

Entities:  

Mesh:

Year:  2015        PMID: 26440366      PMCID: PMC4948203          DOI: 10.1089/thy.2015.0297

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  27 in total

1.  Strict criteria should be applied in the diagnosis of encapsulated follicular variant of papillary thyroid carcinoma.

Authors:  John K C Chan
Journal:  Am J Clin Pathol       Date:  2002-01       Impact factor: 2.493

2.  Interobserver and intraobserver reproducibility in the histopathology of follicular thyroid carcinoma.

Authors:  Brigitte Franc; Pauline de la Salmonière; Françoise Lange; Catherine Hoang; Albert Louvel; Anne de Roquancourt; Françoise Vildé; Gilles Hejblum; Sylvie Chevret; Claude Chastang
Journal:  Hum Pathol       Date:  2003-11       Impact factor: 3.466

Review 3.  Our approach to follicular-patterned lesions of the thyroid.

Authors:  Zubair W Baloch; Virginia A LiVolsi
Journal:  J Clin Pathol       Date:  2006-06-23       Impact factor: 3.411

4.  Management of follicular thyroid carcinoma should be individualised based on degree of capsular and vascular invasion.

Authors:  C J O'Neill; L Vaughan; D L Learoyd; S B Sidhu; L W Delbridge; M S Sywak
Journal:  Eur J Surg Oncol       Date:  2010-12-08       Impact factor: 4.424

5.  Morbidity and mortality in follicular thyroid cancer.

Authors:  L J DeGroot; E L Kaplan; M S Shukla; G Salti; F H Straus
Journal:  J Clin Endocrinol Metab       Date:  1995-10       Impact factor: 5.958

6.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

7.  Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma.

Authors:  Ricardo V Lloyd; Lori A Erickson; Mary B Casey; King Y Lam; Christine M Lohse; Sylvia L Asa; John K C Chan; Ronald A DeLellis; H Ruben Harach; Kennichi Kakudo; Virginia A LiVolsi; Juan Rosai; Thomas J Sebo; Manuel Sobrinho-Simoes; Bruce M Wenig; Marick E Lae
Journal:  Am J Surg Pathol       Date:  2004-10       Impact factor: 6.394

Review 8.  The demise of follicular carcinoma of the thyroid gland.

Authors:  V A LiVolsi; S L Asa
Journal:  Thyroid       Date:  1994       Impact factor: 6.568

9.  Follicular thyroid carcinoma: histology and prognosis.

Authors:  Alessandra D'Avanzo; Patrick Treseler; Philip H G Ituarte; Mariwil Wong; Leanne Streja; Francis S Greenspan; Allan E Siperstein; Quan-Yang Duh; Orlo H Clark
Journal:  Cancer       Date:  2004-03-15       Impact factor: 6.860

10.  Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients.

Authors:  Marco Volante; Stefania Landolfi; Luigi Chiusa; Nicola Palestini; Manuela Motta; Alessandra Codegone; Bruno Torchio; Mauro G Papotti
Journal:  Cancer       Date:  2004-03-01       Impact factor: 6.860

View more
  9 in total

1.  Prognosis of FTC compared to PTC and FVPTC: findings based on SEER database using propensity score matching analysis.

Authors:  Zeming Liu; Wen Zeng; Lei Huang; Zhaoyuan Wang; Min Wang; Ling Zhou; Danyang Chen; Haifeng Feng; Wei Zhou; Liang Guo
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

2.  Establishment and validation of a nomogram model for predicting the survival probability of differentiated thyroid carcinoma patients: a comparison with the eighth edition AJCC cancer staging system.

Authors:  Ruyi Zhang; Mei Xu; Xiangxiang Liu; Miao Wang; Qiang Jia; Shen Wang; Xiangqian Zheng; Xianghui He; Chao Huang; Yaguang Fan; Heng Wu; Ke Xu; Dihua Li; Zhaowei Meng
Journal:  Endocrine       Date:  2021-04-06       Impact factor: 3.633

3.  FOLLICULAR THYROID CARCINOMA - CLINICAL AND DIAGNOSTIC FINDINGS IN A 20-YEAR FOLLOW UP STUDY.

Authors:  C I Badulescu; D Piciu; D Apostu; M Badan; A Piciu
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Apr-Jun       Impact factor: 0.877

4.  Identification of CHEK1, SLC26A4, c-KIT, TPO and TG as new biomarkers for human follicular thyroid carcinoma.

Authors:  Anne-Marie Makhlouf; Zhanna Chitikova; Marc Pusztaszeri; Margaret Berczy; Celine Delucinge-Vivier; Frederic Triponez; Patrick Meyer; Jacques Philippe; Charna Dibner
Journal:  Oncotarget       Date:  2016-07-19

5.  Mutation profiles of follicular thyroid tumors by targeted sequencing.

Authors:  Huanli Duan; Xiaoding Liu; Xinyu Ren; Hui Zhang; Huanwen Wu; Zhiyong Liang
Journal:  Diagn Pathol       Date:  2019-05-10       Impact factor: 2.644

6.  Different Threshold of Malignancy for RAS-like Thyroid Tumors Causes Significant Differences in Thyroid Nodule Practice.

Authors:  Kennichi Kakudo
Journal:  Cancers (Basel)       Date:  2022-02-05       Impact factor: 6.639

7.  Rapid methods to create a positive control and identify the PAX8/PPARγ rearrangement in FNA thyroid samples by molecular biology.

Authors:  Emilia Vuttariello; Elio Biffali; Raimondo Pannone; Anna Capiluongo; Mario Monaco; Valentina Sica; Concetta Aiello; Marco Matuozzo; Maria Grazia Chiofalo; Gerardo Botti; Gennaro Chiappetta
Journal:  Oncotarget       Date:  2018-04-10

8.  FAM172A promotes follicular thyroid carcinogenesis and may be a marker of FTC.

Authors:  Pei-Pei Xu; Su Zeng; Xiao-Tian Xia; Zi-Heng Ye; Mei-Fang Li; Ming-Yun Chen; Tian Xia; Jing-Jing Xu; Qiong Jiao; Liang Liu; Lian-Xi Li; Ming-Gao Guo
Journal:  Endocr Relat Cancer       Date:  2020-11       Impact factor: 5.678

9.  Combining data to perform population-based observational studies: know your sources. The case of thyroid cancer in Belgium.

Authors:  Brigitte Decallonne; Bérengère Snyers; Nathalie Elaut; Bernard Peene; Julie Verbeeck; Annick Van den Bruel; Harlinde De Schutter
Journal:  Arch Public Health       Date:  2022-03-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.